Acta Diabetologica · 2021 · 33 citations · 37 references
Veterinary MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyInflammationLipid BiochemistryCardiovascular DiseaseFamilial HypercholesterolemiaInflammatory BiomarkersInflammatory SignalingLipid-lowering TherapyMetabolic InflammationArterial Pulse Wave VelocityAtherosclerosis RiskHigh-intensity Statin TreatmentInflammatory Cardiac BiomarkersLow-density Lipoprotein Cholesterol ReductionNeutrophil-to-lymphocyte RatioPcsk9 Inhibitor TherapyPcsk9 Inhibitors
AIMS: Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. METHODS: In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. RESULTS: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Finally, simple regression analyses showed that ∆ PWV was significantly associated with ∆ LDL-C (p < 0.01), ∆ NC and ∆ MHR (p value for both < 0.05). CONCLUSIONS: In conclusion, PCSK9-i therapy significantly improved lipid and inflammatory profiles and PWV values in FH subjects; our results support the positive effect of PCSK9-i in clinical practice.
37
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano, Ian Graham, Guy De Backer et al. · European Heart Journal · 2016 · 3.2K citations · Full text
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean‐Claude Tardif, Simon Kouz, David D. Waters et al. · New England Journal of Medicine · 2019 · 3K citations · Full text
Pathogenesis of Atherosclerosis
Erling Falk · Journal of the American College of Cardiology · 2006 · 1.8K citations
Effect of Statin Therapy on C-Reactive Protein Levels
Michelle A. Albert, Ellie Danielson, Nader Rifai et al. · JAMA · 2001 · 1.7K citations